"2023 was a year when we increased our presence in the microbiome testing market and took a leap forward in our commercialization journey. We have further developed and enhanced our GA-map® platform, entered into new distribution agreements, and begun approaching other international markets. During the year we also launched our new offering to research customers and initiated a collaboration to commercialize GA-map® to the consumer market."
Q4 2023 (
- Operating income amounted to
NOK 6,4 million (5,7) -
Sales amounted to
NOK 3,8 million (3,5) -
Net profit/loss amounted to
NOK -6,7 million (-7,8) -
Total assets amounted to
NOK 53,5 million (64,4) - Equity ratio amounted to 60 % (69 %)
-
Earnings per share amounted to
NOK -0,17 (-0,31)
Q1-Q4 2023 (
- Operating income amounted to
NOK 23,2 million (20,7) -
Sales amounted to
NOK 14,1 million (11,2) -
Net profit/loss amounted to
NOK -23,8 million (-28,3) -
Total assets amounted to
NOK 53,5 million (64,4) - Equity ratio amounted to 60 % (69 %)
-
Earnings per share amounted to
NOK -0,62 (-1,13)
Highlights during Q4 2023
- Total operating income of
NOK 6,4 million in Q4 2023 (NOK 5,7 million) reflecting a growth of 12% compared to Q4 2022. Net loss wasNOK -6,7 million compared toNOK -7,8 million in the corresponding quarter of 2022.
-
Sales revenues of
NOK 3,8 million (NOK 3,5 million ) in Q4 2023, a 9% growth compared to Q4 2022. For 2023 in total, sales ended atNOK 14,1 million (NOK 11,2 million ), a 27% growth compared to 2022.
-
In Q4,
Luminex Corporation distributed a whitepaper describing how the GA-map® Dysbiosis Test utilizes the xMAP® technology for microbiome profiling. This whitepaper was sent out in several mailings to all Luminex customers globally and demonstrates for thousands of xMAP® users the benefits of running GA-map® on their Luminex xMAP® instruments.
-
On
October 12 , GA announced that the Company had successfully completed a pilot project and initiated a development project in collaboration with a pharmaceutical company to develop a new microbiome-based rapid companion diagnostic PCR test. The development project's goal is to provide clinicians with a decision tool for prescribing treatment and monitoring treatment effects aimed at faster clinical decision-making.
-
On
October 24 , GA announced that the Company had launched GA-map® Discovery - a new microbiome profiling service directed to research customers in academia and industry. GA-map® Discovery is GA's first dedicated offering to the research market which is currently witnessing considerable growth.
-
On
November 2 , GA announced that the Company had issued a direct share issue of approximatelyNOK 10,5 million . at a subscription price ofNOK 0.79 per share. Subscribers of the directed issue were a group of existing shareholders, including the Company's main shareholderBio-Rad Laboratories . To reduce the dilution effect from the directed issue, the Company carried out a subsequent offering at the same subscription price as in the directed issue. The subsequent offering was subscribed toNOK 3,1 million , or approximately 35 percent. After the offering, the number of shares in GA increased to 42,157,355 shares and the total share capital toNOK 25,294,413 .
-
On
November 16 , GA announced that the Company recently presented its proprietary microbiome testing platform GA-map® at xMAP® Connect EMEA, a conference byLuminex Corporation - aDiaSorin Company . The presentation addressed how effective GA's microbiome testing platform works together with Luminex's xMAP® technology, and we experienced strong interest for GA-map®.
-
On
November 20 , GA held an Extraordinary General Meeting. The General Meeting formally decided on the share capital increase and all items on the agenda were approved as proposed.
-
On
November 23 , GA published the outcome of option exercise of series TO 2. No warrants of series TO 2 have been exercised. The background is that the subscription price, when exercising warrants of series TO 2 during the entire exercise period, exceeded the current share price.
-
On
December 13 , GA published a summary of the current year's product development and ongoing projects. The Company now looks ahead to the value-adding milestones in 2024.
-
On
December 21 , GA announced a collaboration with Comono AS to develop a digital business platform for microbiome testing for the consumer market. Microbiome testing will be performed with the GA-map® technology. The digital platform is already in advanced development, and a joint venture has been established to complete the development and commercialize the consumer offering with an expected launch in Q2 2024. This will initially target the Nordic consumer market through online sales. By combining GA's validated testing platform and expertise in microbial analysis with advanced software, GA makes a strategic move into the microbiome consumer testing market with the aim to deliver a unique and user-friendly experience for consumers.
Highlights after the end of the period
- On
January 10 , GA announced that the subsequent offering to existing shareholders, for which the subscription period ended onDecember 22, 2023 , has now been registered with theNorwegian Register ofBusiness Enterprises .
-
On
February 26 , GA announced that the GA-map® Sample Collection Kit had obtained CE-IVDR marking according to In Vitro Diagnostic Regulation (EU) 2017/746. The GA-map® Sample Collection Kit is now commercially available and will be offered as a stand-alone product for researchers and laboratories in need of fecal collection sampling, as well as in a direct-to-consumer setting.
For further information, please contact:
E-mail: rh@genetic-analysis.com
E-mail: ea@genetic-analysis.com
About Genetic Analysis:
For more general information: www.genetic-analysis.com
Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/
Interested in reading more about GA's products? Please visit ga-map.com
https://news.cision.com/genetic-analysis-as/r/year-end-report-january---december-2023,c3937656
https://mb.cision.com/Main/20846/3937656/2637143.pdf
https://mb.cision.com/Public/20846/3937656/84956eb1929141e8.pdf
(c) 2024 Cision. All rights reserved., source